We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

ctDNA-Based Liquid Biopsy Test Screens for 10 Common Cancers in Single Blood Draw

By LabMedica International staff writers
Posted on 11 May 2023
Print article
Image: LucenceINSIGHT enables early cancer detection through a single blood test (Photo courtesy of Freepix)
Image: LucenceINSIGHT enables early cancer detection through a single blood test (Photo courtesy of Freepix)

As the elderly population increases, there's an escalating crisis in cancer, with new cases being reported in the millions annually. The shortfall in screening resources and poor adoption of conventional cancer screening methods result in most patients being diagnosed at advanced stages. Detecting cancer early, when it is still highly treatable, can avert unnecessary deaths due to the disease. A pioneering multi-cancer early detection (MCED) test now offers the potential for early cancer detection by screening for the risk of up to 10 cancers in a simple blood draw.

Lucence Health (Palo Alto, CA, USA) has introduced LucenceINSIGHT, a ctDNA-based liquid biopsy test capable of screening for 10 common cancers with a single blood draw. It is important to note that 78% of global cancer deaths are attributable to cancers for which there is no routine screening recommended. Blood testing could render the screening of various cancer types more accessible and convenient for people without symptoms.

LucenceINSIGHT identifies cancer-linked changes in DNA fragments found in the blood. These fragments, also referred to as circulating tumor DNA or ctDNA, are released into the bloodstream from cancer cells. Sophisticated sequence analysis is employed by the test to predict the site of origin. Results are presented as areas of concern, which healthcare providers may choose to investigate further if needed. Utilizing Lucence's unique next-generation sequencing technology, LucenceINSIGHT screens for cancer risks with a sensitivity rate of 73% and a specificity rate of 96%.

“Our mission is early cancer detection through a single blood test, when cancer is most treatable hopefully for cure,” said Lucence CEO and Medical Director Dr. Min-Han Tan. “We strongly believe in collaboration with partners who are motivated to overcome cancer together globally.”

Related Links:
Lucence Health 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more